PACLITAXEL EBEWE 6mg / ml concentrate for solution for infusion medication leaflet

L01CD01 paclitaxel • Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Taxanes

Paclitaxel is a chemotherapy agent used in the treatment of various cancers, including breast, ovarian, and lung cancer. It works by inhibiting cell division, stabilizing microtubules, and preventing chromosome separation during mitosis.

The medication is administered intravenously, as directed by a doctor, usually once every three weeks. It is important for patients to follow the treatment regimen and undergo regular tests to monitor the therapy's effects.

Patients should be aware of potential side effects, such as nausea, hair loss, or peripheral neuropathy. It is important to inform the doctor of any unusual symptoms.

Common side effects include nausea, hair loss, and peripheral neuropathy. In rare cases, severe reactions such as myelosuppression or allergic reactions may occur. Patients should be informed of these risks before use.

General data about PACLITAXEL EBEWE 6mg / ml

Substance: paclitaxel

Date of last drug list: 01-09-2021

Commercial code: W43372006

Concentration: 6mg / ml

Pharmaceutical form: concentrate for solution for infusion

Packing volume: 100ml

Product type: generic

Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

Manufacturer: EBEWE PHARMA GES.M.B.H. NFG. KG - AUSTRIA

Holder: EBEWE PHARMA GES.M.B.H. NFG. KG - AUSTRIA

Number: 13701/2021/06

Shelf life: 3 years

Concentrations available for paclitaxel

5mg/ml, 6mg/ml

Other substances similar to paclitaxel